Simon Hawke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10937172/publications.pdf

Version: 2024-02-01

27 papers	1,500 citations	516710 16 h-index	526287 27 g-index
27 all docs	27 docs citations	27 times ranked	1927 citing authors

#	Article	IF	Citations
1	Circulating Memory B Cells in Early Multiple Sclerosis Exhibit Increased IgA+ Cells, Globally Decreased BAFF-R Expression and an EBV-Related IgM+ Cell Signature. Frontiers in Immunology, 2022, 13, 812317.	4.8	10
2	Peripheral Bâ€cell dysregulation is associated with relapse after longâ€term quiescence in patients with multiple sclerosis. Immunology and Cell Biology, 2022, 100, 453-467.	2.3	13
3	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 722237.	2.4	8
4	Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment. Journal of Neuroimmunology, 2020, 349, 577392.	2.3	13
5	RFC1 expansions can mimic hereditary sensory neuropathy with cough and SjÃ¶gren syndrome. Brain, 2020, 143, e82-e82.	7.6	25
6	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, 537.	2.4	27
7	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	3.6	17
8	IgG 3 + B cells are associated with the development of multiple sclerosis. Clinical and Translational Immunology, 2020, 9, e01133.	3.8	23
9	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	1.9	108
10	Exosomal microRNA signatures in multiple sclerosis reflect disease status. Scientific Reports, 2017, 7, 14293.	3.3	196
11	Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients. Multiple Sclerosis Journal, 2016, 22, 1883-1887.	3.0	27
12	Differential Toxicity of Antibodies to the Prion Protein. PLoS Pathogens, 2016, 12, e1005401.	4.7	54
13	Epitope-specific anti-prion antibodies upregulate apolipoprotein E and disrupt membrane cholesterol homeostasis. Journal of General Virology, 2010, 91, 3105-3115.	2.9	7
14	Unswitched immunoglobulin M response prolongs mouse survival in prion disease. Journal of General Virology, 2009, 90, 777-782.	2.9	21
15	A role for B lymphocytes in anti-infective prion therapies?. Expert Review of Anti-Infective Therapy, 2007, 5, 631-638.	4.4	2
16	PrP glycoforms are associated in a strain-specific ratio in native PrPSc. Journal of General Virology, 2005, 86, 2635-2644.	2.9	63
17	Disease-Associated Prion Protein Elicits Immunoglobulin M Responses In Vivo. Molecular Medicine, 2004, 10, 104-111.	4.4	13
18	PrPSc Binding Antibodies Are Potent Inhibitors of Prion Replication in Cell Lines. Journal of Biological Chemistry, 2004, 279, 39671-39676.	3.4	62

#	Article	IF	Citations
19	Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 2003, 422, 80-83.	27.8	457
20	Regional heterogeneity of cellular prion protein isoforms in the mouse brain. Brain, 2003, 126, 2065-2073.	7.6	112
21	Distant interactions between dimorphisms in HLA-DR4 radically affect recognition of defined peptides by a specific T cell clone. International Immunology, 1999, 11, 835-843.	4.0	4
22	Cross-restriction of a T cell clone to HLA-DR alleles associated with rheumatoid arthritis: Clues to arthritogenic peptide motifs. Arthritis and Rheumatism, 1999, 42, 1040-1050.	6.7	13
23	Long-Term Persistence of Activated Cytotoxic T Lymphocytes after Viral Infection of the Central Nervous System. Journal of Experimental Medicine, 1998, 187, 1575-1582.	8.5	104
24	Recruitment, activation and proliferation of CD8+ memory T cells in an immunoprivileged site. European Journal of Immunology, 1997, 27, 3259-3268.	2.9	27
25	Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Trends in Immunology, 1996, 17, 307-311.	7.5	56
26	Differences in processing of an autoantigen by DR4:Dw4.2 and DR4:Dw14.2 antigen-presenting cells. European Journal of Immunology, 1995, 25, 2119-2122.	2.9	10
27	T cell responses to human recombinant acetylcholine receptor-Î± subunitin myasthenia gravis and controls. European Journal of Immunology, 1992, 22, 1553-1559.	2.9	28